Mesoblast Ltd (ASX: MSB) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Mesoblast Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.01 billion
P/E Ratio 2.16
Dividend Yield N/A
Shares Outstanding 647.40 million
Earnings per share -0.156
Dividend per share N/A
Year To Date Return -30.89%
Earnings Yield 46.27%
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Mesoblast Ltd (ASX: MSB)
Latest News

MSB ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Mesoblast Ltd

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

MSB Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Dec 2021 $1.56 $-0.06 -3.72% 2,229,676 $1.61 $1.61 $1.55
02 Dec 2021 $1.62 $-0.03 -1.82% 1,287,122 $1.65 $1.65 $1.60
01 Dec 2021 $1.65 $-0.05 -2.94% 1,377,042 $1.69 $1.70 $1.65
30 Nov 2021 $1.70 $0.01 0.59% 1,859,847 $1.68 $1.72 $1.66
29 Nov 2021 $1.69 $-0.02 -1.17% 2,238,272 $1.73 $1.74 $1.68
26 Nov 2021 $1.71 $-0.05 -2.85% 506,224 $1.76 $1.77 $1.71
25 Nov 2021 $1.76 $0.02 1.16% 847,383 $1.74 $1.77 $1.72
24 Nov 2021 $1.73 $0.02 1.17% 1,738,088 $1.72 $1.76 $1.70
23 Nov 2021 $1.71 $0.03 1.79% 1,379,034 $1.69 $1.73 $1.69
22 Nov 2021 $1.68 $-0.04 -2.33% 2,188,486 $1.73 $1.77 $1.68
19 Nov 2021 $1.72 $-0.01 -0.58% 1,564,767 $1.73 $1.76 $1.72
18 Nov 2021 $1.73 $-0.08 -4.44% 2,698,705 $1.82 $1.82 $1.73
17 Nov 2021 $1.80 $0.07 4.03% 2,686,426 $1.76 $1.82 $1.73
16 Nov 2021 $1.74 $-0.17 -8.95% 6,833,071 $1.92 $1.93 $1.73
15 Nov 2021 $1.90 $0.20 11.76% 9,887,591 $1.72 $1.95 $1.72
12 Nov 2021 $1.70 $0.05 3.04% 1,172,503 $1.66 $1.70 $1.66
11 Nov 2021 $1.65 $-0.04 -2.37% 1,141,292 $1.67 $1.68 $1.64
10 Nov 2021 $1.69 $0.00 0.00% 662,196 $1.70 $1.70 $1.67
09 Nov 2021 $1.69 $0.02 1.20% 1,058,177 $1.67 $1.72 $1.64
08 Nov 2021 $1.67 $-0.04 -2.35% 949,916 $1.71 $1.73 $1.66
05 Nov 2021 $1.71 $0.02 1.18% 1,510,108 $1.69 $1.73 $1.69
04 Nov 2021 $1.69 $0.02 1.20% 995,556 $1.67 $1.69 $1.65

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
07 Jul 2021 Silviu Itescu Issued 1 $2,412,000
Issue of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Michael Robert Spooner Non-Executive Director Sep 2004
Mr Spooner has served on the Board of Directors since 2004. During this period he has filled various roles including as Chairman from the date of the ASX public listing in 2004 until 2007. Over the past several years Mr Spooner has served on the board of directors in various capacities at several Australian and international biotechnology companies, including BiVacor Pty Ltd (2009- 2013), Advanced Surgical Design & Manufacture Limited (2010-2011), Peplin, Inc. (2004-2009), Hawaii Biotech, Inc. (2010-2012), Hunter Immunology Limited (2007-2008), and Ventracor Limited (2001-2003). He has been the Chairman of Simavita Ltd since May 2016 and Chairman of MicrofluidX since February 2018. Prior to returning to Australia in 2001, Mr Spooner spent much of his career internationally where he served in various roles including as a partner to PA Consulting Group, a UK-based management consultancy, and a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong. In addition Mr Spooner has owned and operated several international companies providing services and has consulted to a number of U.S. and Asian public companies. Mr Spooner provides executive management, commercial, business strategy and accounting expertise as well as established relationships with investment firms and business communities worldwide
Professor Silviu Itescu Chief Executive OfficerExecutive Director Jun 2004
Dr Itescu is our Chief Executive Officer (CEO). He has served our board of directors since our founding in 2004, was Executive Director from 2007 to 2011, and became CEO and Managing Director in 2011. Prior to founding Mesoblast in 2004, Dr Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He has been a faculty member of Columbia University in New York, and of Melbourne and Monash universities in Australia. In 2011, Dr Itescu was named BioSpectrum Asia Person of the Year. In 2013, he received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. Dr Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies
Mr Donal Paul O'Dwyer Non-Executive Director Sep 2004
Mr O'Dwyer has served on our board of directors since 2004. He has over 25 years of experience as a senior executive in the global cardiovascular and medical devices industries. From 1996 to 2003, Mr O'Dwyer worked for Cordis Cardiology, the cardiology division of Johnson & Johnson's Cordis Corporation, initially as its president (Europe) and from 2000 as its worldwide president. Prior to joining Cordis, Mr. O'Dwyer worked with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences. Mr. O'Dwyer is on the board of directors of Fisher & Paykel Healthcare Ltd and NIB Holdings Ltd. He also served on the board of Cochlear Ltd for 15 years and retired from their board in October 2020. With his experience as a senior executive and a director, as well as his experience in the cardiovascular and medical devices industries, Mr. O'Dwyer provides business, science, engineering and management expertise.
Dr Eric A Rose Non-Executive Director Apr 2013
Dr Rose has served on our board of directors since 2013. From 2007 through 2021, Dr Rose was with SIGA Technologies initially as CEO from 2007 to 2017 and then Chairman. From 2008 through 2012, Dr Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine. From 1994 through 2007, Dr Rose served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 through 1992, he led the Columbia Presbyterian heart transplantation program in the United States. Dr Rose currently sits on the board of directors of ABIOMED. His experience as a surgeon, researcher and businessman provides medical, pharmaceutical, scientific and industry expertise.
Mr William (Bill) A Burns Non-Executive DirectorVice-Chairman Mar 2014
Mr Burns has served on our board of directors since 2014 and was appointed Vice Chairman in 2016. He spent his entire management career at the Beecham Group and F. Hoffmann-La Roche Ltd. He was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the board of directors of F. Hoffmann-La Roche Ltd. until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non-Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp. from 2014 until its sale to Acorda Therapeutics Inc. in 2016. Mr Burns is also a member of the Oncology Advisory Board of the Universities of Cologne/Bonn in Germany. In 2014, he was appointed a trustee of the Institute of Cancer Research, London, and from March 2016 until April 2020 a Governor of The Wellcome Trust in London, UK. His extensive experience in the pharmaceutical industry, specifically as a member of the board of directors of other pharmaceutical companies, provides pharmaceutical, healthcare, industry, leadership and management expertise.
Mr Joseph R Swedish Non-Executive DirectorNon-Executive Chairman Jun 2018
Mr Swedish has more than two decades of healthcare leadership experience as the CEO for major United States healthcare enterprises. Most recently, he has served as Executive Chairman, President and CEO of Anthem Inc., America's leading health benefits provider. Prior to joining Anthem, Mr Swedish was CEO for several major integrated healthcare delivery systems, including Trinity Health and Colorado's Centura Health. Currently, he sits on the board of directors of IBM Corporation, CDW Corporation, and Centrexion Therapeutics. Mr Swedish is a member and previously Chairman of Duke University's Fuqua School of Business Board of Visitors. Previously, he was Chairman of the Catholic Health Association and the America's Health Insurance Plans.
Ms Shawn Cline Tomasello Non-Executive Director Jul 2018
Mr Tomasello,with more than 30 years' experience in the pharmaceutical and biotech industries, Mr Tomasello has commercial and transactional experience. Since 2015, Ms Tomasello had been Chief Commercial Officer at leading immunooncology cell therapy company Kite Pharma, where she played a pivotal role in the company's acquisition in 2017 by Gilead Sciences for $11.9 billion. Prior to this she served as Chief Commercial Officer at Pharmacyclics, Inc., which was acquired in 2015 by AbbVie, Inc. for $21 billion. Ms Tomasello previously was President of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues, and was instrumental in various global expansion and acquisition strategies. She has also held key positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. Ms Tomasello currently serves on the Board of Directors of Gamida Cell, Ltd. and UroGen Pharma, Ltd, TCR2 Therapeutics, and 4D Molecular Therapeutics. She previously served on the board of Principia Biopharma; acquired by Sanofi, Abeona Therapeutics (resigned), Clementia Pharmaceuticals, Inc. which was acquired by Ipsen, SA, and Diplomat Specialty which was acquired by United Healthcare. Her experience in the pharmaceutical and biotech industries, particularly in the commercial and transactional fields, provides industry, leadership and management expertise.
Mr Philip J. Facchina Non-Executive Director Mar 2021
Mr Facchina brings more than 35 years of experience in corporate strategy, capital markets, finance, and business development across several industries, including healthcare. Since 2018, Mr. Facchina has been Chief Strategy Officer at SurgCenter Development, the largest privately held operator of ambulatory surgery centers in the US, overseeing the company's strategic relationships, including its relationships with the broad US ASC market, certain hospital systems and other market constituents. Prior to SurgCenter, Mr Facchina spent two decades in the public and private capital markets, where he managed liquid and illiquid portfolios, and managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take-privates. From 2008 to 2017, Mr. Facchina served as a Partner, Co-Portfolio Manager and the Chief Operating Officer of Ramsey Asset Management, an institutional investment management firm, and from 1998 to 2008 Mr. Facchina led the technology, media and communications and healthcare investment banking groups of FBR Capital Markets. Mr Facchina currently serves as an independent director for ViON 84 Corporation and Millennium Global Treasury Services, and is Advisor to the CEO of Johanna Foods Inc, where he heads the Audit Committee and he also serves as an advisor to New Markets Venture Partners. Previously, among other directorships and committee posts, Mr Facchina served on the Board of, where he led Corporate Governance. Mr Facchina is a qualified financial expert for SEC and NASDAQ purposes
Mr Charlie Harrison Company Secretary Sep 2014
Ms Niva Sivakumar Joint Company Secretary Oct 2019
Josh Muntner Chief Financial Officer
Fred Grossman Chief Medical Officer
Dagmar Rosa-Bjorkeson Chief Operating Officer
Charlie Harrison Company Secretary
Justin Horst Head of Manufacturing
Geraldine Storton Head of Regulatory Affairs and Quality Management
Paul Simmons Head of Research and New Product Development
Niva Sivakumar Joint Company Secretary
Michael Schuster Pharma Partnering

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
JP Morgan Nominees Australia Pty Limited 121,770,725 18.77%
HSBC Custody Nominees (Australia) Limited 98,085,940 15.12%
Professor Silviu Itescu 67,751,838 10.44%
Citicorp Nominees Pty Limited 33,879,000 5.22%
UBS Nominees Pty Ltd 11,867,428 1.83%
Thorney Holdings Pty Ltd 10,000,000 1.54%
TIGA Trading Pty Ltd 10,000,000 1.54%
BNP Paribas Nominees Pty Ltd Six Sis Ltd 9,345,724 1.44%
Independent Asset Management Pty Limited 7,870,558 1.21%
Merrill Lynch (Australia) Nominees Pty Limited 5,796,431 0.89%
National Nominees Limited 4,383,937 0.68%
BNP Paribas Noms Pty Ltd 4,018,197 0.62%
Mr Gregory John Matthews & Mrs Janine Marie Matthews 3,918,942 0.60%
CS Third Nominees Pty Limited 3,700,135 0.57%
BNP Paribas Nominees Pty Ltd 2,977,948 0.46%
HSBC Custody Nominees (Australia) Limited i 2,402,815 0.37%
Kentgrove Capital Pty Ltd 2,000,100 0.31%
Tigcorp Nominees Pty Ltd 1,995,000 0.31%
National Nominees Limited I 1,888,878 0.29%
Lalp Pty Ltd 1,647,144 0.25%